F9 nuclear extract (Retinoic acid treated)

Catalog No: 36113 Format: 200 µg ¥44,000 Buy

Contents

2 x 100 µg of F9 nuclear extract (Retinoic acid treated) at 2.5 µg/µl.

Background

F9 nuclear extract (Retinoic acid treated) was prepared from cell cultures of the mouse teratocarcinoma F9 stem cell line. This cell line expresses characteristics of early mouse embryonal cells and is considered to be nullipotent because of its inability to spontaneously differentiate. However, introduction of chemical agents, such as retinoic acid (RA), or transfection with oncogenic sequences, such as SV40 large T antigen, can induce differentiation of these cells. F9 cells readily differentiate into an endodermal-like derivative phenotype, but possess the ability to differentiate into derivatives of all three germ layers under the appropriate culture conditions, suggesting that these cells may be pluripotent. The F9 stem cell line is widely used in research to study the biomolecular mechanisms underlying differentiation.

Application Notes

F9 nuclear extract (Retinoic acid treated) is specifically recommended for studies related to differentiation and in stem cell research.

Extract Origin

Murine testes (Embryonal Carcinoma)

Extract Composition

F9 nuclear extract (Retinoic acid treated) is supplied in Dilution Buffer (20 mM Hepes (pH 7.9), 100 mM KCl, 1 mM MgCl2, 20% glycerol, 0.5 mM PMSF and 0.5 mM DTT). Cells were treated with 1 µM Retinoic acid for 48 hours. Retinoic acid is refreshed after 24 hours. Cells must be grown on plates coated with 0.1% gelatin.

Quality Control

Each lot has been tested for GATA-4 activation by using TransAM® Kits.

Storage

To ensure stability, extracts should be stored at -80°C.

We recommend aliquoting the extracts into single-use fractions and then storing them at -80°C. This eliminates repeated freeze/thaw cycles.

Guarantee

This product is guaranteed for 6 months from date of receipt.

This product is for research use only and is not for use in diagnostic procedures.